All News

Physical and sexual violence while on a date can have long-term traumatic effects for teens and adolescents. A metanalysis examines whether prevention programs are effective at reducing the incidence of violence.

Check out the latest updates and coverage from the American Association of Gynecologic Laparoscopists’ 50th Global Congress on minimally invasive gynecologic surgery.

Black patients may have poorer outcomes during breast cancer treatment than white patients.

A look at what's coming to Contemporary OB/GYN® this week

The addition of palbociclib to endocrine therapy was not associated with preventing disease recurrence in patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative early breast cancer, according to final results of the phase 3 PALLAS trial.

The study results — which were presented during the 2021 San Antonio Breast Cancer Symposium — indicated that elacestrant, a selective estrogen receptor degrader (SERD), led to a 30% reduction in the risk of disease progression or death compared with standard of care in the study population.

What you missed this week on Contemporary OB/GYN®

Vice President Kamala Harris hosted the White House’s first-ever Maternal Health Day of Action Summit on Dec. 7. During the Summit, Harris outlined the administration’s new initiatives and issued a nationwide call to action for public and private sectors to help improve maternal health outcomes.

A recent analysis suggests transfeminine individuals were at a 40% greater risk of developing diabetes than their cisgender counterparts, but this increase in risk was not attributable to gender-affirming hormone therapy.

COVIDmenses is recruiting participants for a study to examine potential effects of COVID-19 vaccination on menstrual health.

Curbside Consults delivers expert perspectives from physicians outside the ob-gyn specialty to provide insight into various health issues affecting pregnant women. In this installment, we learn more about the diagnosis and management of headaches in postpartum patients.

COVID-19 updates and news to know as of December 6, 2021.

A report offers insight into how the Women’s Wellness through Equity and Leadership program performed during its pilot phase.

By July 2021, the FDA had approved or tentatively approved 470 generic versions of medications.

It is essential to expand access to all available, effective cervical cancer screening options for the most vulnerable populations. The targeted use of any particular screening modality in higher-risk populations is not supported by evidence-based guidelines; any effective screening is the priority.

Reliable compensation plans are imperative as health care becomes more complex. Hear from the experts in our new Practice Management column.

Low progesterone levels have been associated with an increased rate of miscarriage.

Here's what's coming up this week on Contemporary OB/GYN.

Wondering what you missed this week?

Contemporary OB/GYN® has aimed to address prevalent topics for our readers, including not only areas related to the pandemic but ones we encounter day to day.

“This vaccine strategy has the potential to be applied to other tumor types,” said Vincent K. Tuohy, PhD, the Mort and Iris November Distinguished Chair in Innovative Breast Cancer Research at Cleveland Clinic Lerner Research Institute, and primary inventor of the vaccine.

In this episode of Pap Talk, we took you with us to the North American Menopause Society's recent Annual Meeting. Sexual health specialist Michael Krychman, MD, sat down with Brooke Faught, NP, to learn more about her work at the Women's Institute for Sexual Health, her role on the NAMS Planning Committee, and her tips for talking trauma with patients.

Patients Desiring Immediate Postpartum Sterilization Should Not Be Required to Wait 30 Days.

Olaparib, which was granted priority review by the FDA, has been shown to improve invasive disease-free survival for patients with BRCA-mutated HER2-negative high-risk early breast cancer.

Retifanlimab demonstrated encouraging antitumor activity with favorable tolerability in patients with recurrent microsatellite instability–high or mismatch repair deficient endometrial cancer, according to data from the phase 1 POD1UM-101 trial.

The US Food and Drug Administration (FDA) is currently investigating whether the new COVID-19 variant will evade current mitigation strategies and diagnostic tools.

An update from infectious disease expert, Rana F. Hamdy, MD, on the Omicron variant of COVID-19.

For girls with additional body weight, using Tanner staging to determine pubertal development may require more care.